France Ophthalmic Devices Market Analysis by Mordor Intelligence
The France ophthalmic devices market stands at a current value of USD 2.35 billion, and analysts project it will reach USD 3.68 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.80% from 2025 to 2030. The steady expansion of the France ophthalmic devices market is underpinned by a surge in premium intraocular lens (IOL) use across public hospitals, wider deployment of optical coherence tomography (OCT) in community practices, and government incentives that reward locally manufactured medical technology. Global brands and French innovators have accelerated product introductions, while artificial-intelligence (AI) software that supports diagnostic imaging is rapidly moving from pilot programs into routine diabetic-retinopathy screening workflows. Technology-driven cost efficiencies are enabling ambulatory surgery centers (ASCs) to capture a higher share of cataract and refractive procedures, adding further momentum to the France ophthalmic devices market. At the same time, reimbursement hurdles for novel hardware and an uneven distribution of ophthalmologists outside large cities temper growth by delaying device adoption in under-served regions, yet the long-term demographic tailwind tied to population ageing keeps the outlook positive.
Key Report Takeaways
- By device type, vision care products led with 63.0% of the France ophthalmic devices market share in 2024; diagnostic & monitoring devices are projected to advance at a 9.95% CAGR through 2030.
- By disease indication, cataract accounted for a 39.2% share of the France ophthalmic devices market size in 2024, while Diabetic Retinopathy is expanding at a 9.11% CAGR over 2025-2030.
- By end-user, hospitals retained 43.6% of spending in the France ophthalmic devices market in 2024; ASCs post the fastest growth at an 8.98% CAGR as the government pushes ambulatory surgery to 80.0% of eligible cases by 2030.
France Ophthalmic Devices Market Trends and Insights
Driver Impact Analysis
Drivers Impact Analysis | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Premium IOL adoption in public hospitals | +1.8 | Nationwide, strongest in Paris, Lyon, Marseille | Medium term (2-4 years) |
OCT penetration in community networks | +1.2 | Urban centers expanding to suburbs | Medium term (2-4 years) |
National diabetic-retinopathy screening programs | +0.9 | Underserved regions | Long term (≥ 4 years) |
Refractive-surgery volume surge | +1.1 | Paris region and large metro areas | Short term (≤ 2 years) |
Government incentives for domestic manufacturing under “France 2030” plan | +0.7 | Nationwide, focused on innovation hubs | Long term (≥ 4 years) |
Integration of AI-based decision-support algorithms into imaging | +1.3 | Initially urban centers, expanding nationally | Medium term (2-4 years) |
Source: Mordor Intelligence
Increasing Adoption of Premium Intraocular Lenses in Post-Cataract Procedures
Surgeons in public hospitals are moving decisively toward presbyopia-correcting and toric IOLs, encouraged by patients who now actively request spectacle independence and by recent Haute Autorité de Santé (HAS) decisions that opened partial reimbursement pathways for select premium implants. Alcon’s VIVITY and PANOPTIX families continue to set the uptake pace, benefiting from the firm’s global supply reach and targeted surgeon-training programs. A 27.0% rise in cataract surgeries since 2020, coupled with 64% of procedures now performed on an ambulatory basis, positions the France ophthalmic devices market for sustained premium-lens growth as the population over 65 swells[1]World Health Organization, “World report on vision,” who.int. Enthusiastic consumer acceptance is evident in surveys that show 38% of cataract patients explicitly asking for high-end IOL models at pre-operative visits, a figure that was barely 10% five years ago. Ongoing innovation in lens-design optics and materials is expected to widen indications, further lifting revenue potential over the forecast horizon.
Rising Penetration of Optical Coherence Tomography in Community Ophthalmology Networks
Compact spectral-domain and swept-source OCT units, bundled with secure cloud image-sharing software, have reached community clinics and optometrist co-management sites, reducing the diagnostic gap between tertiary centers and primary care. Reimbursement for tele-ophthalmology consultations introduced in 2018 eliminates the need for a prior face-to-face visit, allowing earlier macular-pathology detection and streamlining referrals. Evidence from Paris shows that regions deploying OCT at general-practice level reduced vision-loss incidence compared with areas that relied solely on hospital-based services. Suppliers are racing to embed AI-enabled layer-segmentation and automated progression-analysis tools directly onto the OCT console, lowering reading times for busy clinicians and accelerating diagnostic throughput.
National Screening Programs for Diabetic Retinopathy Driving Diagnostic Device Uptake
France’s OPHDIAT telemedical network, now comprising 16 nodes around the capital, has screened more than 15,000 patients with non-mydriatic fundus cameras, detecting diabetic retinopathy in 23.4% of encounters. Uptake of AI-based image analysis has reached 7.2% of nationwide screenings and delivered 100% sensitivity with 94.4% specificity in early studies. The follow-on EviRed project combines OCT and OCT-A into a refreshed grading framework that promises to replace the outdated ETDRS scale, improving risk stratification for the country’s 3.7 million diabetics[2]Carl Zeiss Meditec AG, “ZEISS unveils AI-powered Research Data Platform,” zeiss.com.
Surge in Refractive Surgery Volumes Fueling Demand for Excimer and Femtosecond Lasers
Elective-procedure rebound after pandemic restrictions and aggressive marketing of rapid-recovery laser techniques lifted refractive-surgery volume by 15.0% in 2024, a trend that shows no signs of abating. The myopia epidemic adds structural demand, with forecasts pointing to 6.1% annual growth in the underlying patient pool over the next decade. Advances in wavefront-guided ablation algorithms and high-frequency femtosecond platforms broaden eligibility to complex corneas, while same-day bilateral surgery compresses treatment cycles and maximizes equipment utilization. Manufacturers report order books filled into mid-2026, indicating sustained capital-equipment sales.
Restraints Impact Analysis
Restraints Impact Analysis | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
HAS reimbursement barriers for novel devices | -1.2 | National, highest burden on start-ups | Medium term (2-4 years) |
Shortage of trained ophthalmologists | -0.9 | Rural and semi-urban France | Long term (≥ 4 years) |
High capital cost of advanced surgical platforms for small clinics | -0.7 | Nationwide, emphasis on smaller practices | Short term (≤ 2 years) |
Post-Covid supply-chain disruptions affecting semiconductors | -0.5 | National, cascading impact on production | Short term (≤ 2 years) |
Source: Mordor Intelligence
Stringent HAS Reimbursement Barriers Limiting Novel Device Adoption
The Service Médical Rendu and Amélioration du Service Médical Rendu assessment metrics demand unequivocal clinical-benefit proof before a new product can claim reimbursement, elongating time-to-market and squeezing smaller manufacturers that lack phase-4-level data packages. Even devices that clear the clinical bar face protracted Economic Committee for Health-Care Products price talks, which peg tariffs to cost-effectiveness benchmarks, sometimes below production cost for low-volume specialties. As a result, several innovators sidestep France and pilot in neighboring markets first, delaying domestic access to cutting-edge solutions.
Ophthalmologist Shortage Creating Geographic Disparities in Device Utilization
France counts roughly 3,800 practicing ophthalmologists, far short of the 5,300 positions required for equitable coverage, and with 56.0% concentrated in the Île-de-France, Auvergne-Rhône-Alpes and Provence-Alpes-Côte d’Azur regions. Low professional density in central and southern departments hinders adoption of capital-intensive imaging and laser platforms, as procedure volumes fail to justify investment. Government-supported multi-professional health centers and teleconsultation cabins are emerging stop-gaps, but long training cycles and retirements threaten to worsen the imbalance through 2030.
Segment Analysis
By Device Type: Vision Care Dominates While Diagnostics Accelerate
Vision Care products led the France ophthalmic devices market in 2024, with EssilorLuxottica and other suppliers capturing 63.0% of value through a mix of prescription eyewear, contact lenses and myopia-management interventions. The France ophthalmic devices market size for Vision Care reached USD 1.48 billion in 2024 and will expand steadily on the back of Stellest myopia-control lenses, whose real-world data show an average 67.0% slowdown in axial elongation among school-aged users. Innovations in silicone-hydrogel and water-gradient materials are raising wearing comfort, cementing daily-disposable formats as the fastest-rising subcategory. The corporate push into smart spectacles that integrate heads-up displays and biosensors further differentiates product offerings and deepens barriers to entry.
Diagnostic & Monitoring devices represent the most dynamic slice of the France ophthalmic devices market, exhibiting a 9.95% CAGR through 2030 as OCT units, fundus cameras and perimeters embed AI screening modules. Suppliers are pivoting from hardware margins toward subscription models that bundle cloud analytics and upgrade pathways, smoothing revenue visibility. Miniaturization unlocks sales to community optometrists and pharmacies, significantly raising installed bases in areas formerly underserved by hospital imaging. Collaborative purchasing schemes among regional health agencies are also encouraging bulk orders, reducing unit costs and accelerating refresh cycles.
By Disease Indication: Cataract Leads While Diabetic Retinopathy Accelerates
Cataract therapy maintained the largest share of the France ophthalmic devices market in 2024 at 39.2%, corresponding to USD 921.0 million of the France ophthalmic devices market size. The ambulatory-surgery framework now covers two-thirds of cataract removals, compressing length of stay and raising throughput capacity. Hospitals and ASCs alike are investing in intraoperative aberrometry and femtosecond-laser cataract systems to optimize premium-IOL outcomes, reinforcing the segment’s revenue base. The migration of elderly patients to day-surgery centers accelerates the replacement cycle for phacoemulsification consoles, keeping suppliers’ order pipelines full.
Diabetic-retinopathy solutions deliver the fastest growth, expanding at a 9.11% CAGR. National screening mandates, coupled with AI grading tools, bring previously undiagnosed patients into the treatment funnel, stimulating sales of non-mydriatic fundus cameras and OCT-A modules. Market entrants offering portable, battery-powered imaging units are addressing rural coverage gaps, and their subscription-based software trains continuously on expanding datasets, refining accuracy. The France ophthalmic devices market share for diabetic-retinopathy equipment is set to climb beyond 12% by 2030 as reimbursement shifts to outcome-based bundles that reward early detection.

By End-user: Hospitals Lead While ASCs Show Rapid Growth
Hospitals generated the largest portion of 2024 expenditure, accounting for 43.6% of the France ophthalmic devices market thanks to superior infrastructure, multidisciplinary teams and leverage in procurement contracts with vendors. Flagship institutes such as the Hôpital national des 15-20, which achieved a 97% compliance score in the latest HAS audit, continue to pilot cutting-edge devices that later fan out to provincial centers. High-volume service lines, including cataract and vitrectomy, underpin attractive economics that incentivize continuous equipment renewal.
ASCs, however, are the star growth performers, with an 8.98% CAGR through 2030 as policymakers target 80% same-day surgery penetration[3]Le Quotidien du Médecin, “Comment augmenter son taux de chirurgie ambulatoire à 80 %,” lequotidiendumedecin.fr. Private-equity backing has fueled a wave of acquisitions, raising capital to install premium IOL-optimized operating microscopes and femtosecond platforms previously confined to tertiary hospitals. The France ophthalmic devices market size for ASCs is expected to surpass USD 1 billion by 2029, reflecting patient preference for streamlined pathways and lower infection risk. Specialty ophthalmic clinics trail in scale yet gain relevance by bundling diagnostics, surgery and postoperative rehab under one roof.

Geography Analysis
Paris, Lyon and Marseille anchor the highest technology penetration rates in the France ophthalmic devices market, supported by dense ophthalmologist clusters and research-intensive hospitals that catalyze early adoption. The Île-de-France region alone hosts 16 OPHDIAT screening hubs plus EssilorLuxottica’s newly inaugurated excellence laboratory, reinforcing a virtuous cycle of innovation and clinical validation. These urban centers attract fellowship-trained surgeons proficient with premium IOLs and advanced laser systems, delivering treatment volumes that justify rapid device turnover.
Conversely, rural departments in Centre-Val de Loire, Nouvelle-Aquitaine and Occitanie display lower imaging-equipment density, a disparity closely tied to the national shortage of ophthalmologists. Research correlating practitioner density with odds ratios of low vision confirms that regions below the national median for specialists endure higher impairment rates. Teleconsultation cabins, financed through public–private partnerships, are filling part of the gap by hosting slit lamp attachments, fundus cameras and vision-analysis software, forwarding images to urban reading centers for interpretation. Early audits reveal a 32% reduction in missed glaucoma diagnoses in communes adopting the cabin model versus control sites.
Mobile screening units active for 11 years in Burgundy demonstrate another tool for geographic equity, logging over 18,000 patient encounters and reducing referral delays by 40.0%. The France 2030 industrial strategy earmarks USD 450.0 million in grants and low-interest loans to accelerate domestic medical-device manufacturing, stipulating regional deployment benchmarks that favor historically underserved zones. Complementary digital-health initiatives such as the MEDITWIN virtual-twin consortium promise to personalize pre-operative planning, further democratizing access to sophisticated surgical care across all departments.
Competitive Landscape
The France ophthalmic devices market sits at a moderate consolidation level, with the top three groups— EssilorLuxottica SA, Alcon, Inc. and Johnson & Johnson Vision Care—commanding about 66.0% of Vision Care, surgical and diagnostic revenues. EssilorLuxottica leverages vertical integration, a portfolio of heritage and fashion brands, and a strategic pivot into med-tech, evident in its purchase of Heidelberg Engineering and commitment to smart-lens R&D. The company posted USD 30.04 billion in global revenue in 2024, up 4.38% year-on-year, and allocated USD 415.0 million to French R&D and manufacturing expansions.
Alcon focuses on premium IOLs and advanced cataract platforms, reporting high-single-digit revenue growth in implantables for Q2 2024. Rapid uptake of its PanOptix trifocal lens and Vivity non-diffractive EDOF model reflects strong surgeon confidence and direct-to-consumer educational outreach. Johnson & Johnson Vision is consolidating its presence through multifocal contact lenses and the Catalys femtosecond laser, pairing hardware with personalized planning software.
Domestic challengers such as Precilens, Lumibird Medical and Quantel Medical thrive in niche optics, lasers and ultrasound biomicroscopy, often enjoying proximity to France’s defense and aerospace industrial base for precision machining capabilities. Start-ups including OpthAI, which secured CE marking for AI-based fundus-image triage with 100.0% sensitivity, illustrate the shift toward software-as-a-medical-device competitive advantage jfo. Partnerships—such as Zeiss’s collaboration with Boehringer Ingelheim to co-develop retinal-disease analytics—underscore the importance of cross-sector alliances to accelerate pipeline progression and share regulatory risk.
France Ophthalmic Devices Industry Leaders
-
EssilorLuxottica SA
-
Alcon Inc.
-
Carl Zeiss Meditec AG
-
Johnson & Johnson Vision Care
-
Topcon Corporation
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- May 2025: EssilorLuxottica inaugurated a new excellence laboratory in Paris, positioning the site as a hub for smart-lens prototyping and clinical collaboration. The facility underlines national efforts to anchor high-value manufacturing in France.
- January 2024: The MEDITWIN consortium launched with governmental backing, aiming to build virtual twins that personalize ophthalmic treatment pathways and integrate seamlessly with imaging devices.
- August 2024: Haute Autorité de Santé issued a favorable reimbursement decision for EYLEA (aflibercept) in neovascular age-related macular degeneration, reinforcing policy support for evidence-backed innovations.
- May 2024: The Choose France Summit announced health-care investment pledges of EUR 15 billion (USD 16.3 billion), signaling sustained capital inflows to medical technology projects.
France Ophthalmic Devices Market Report Scope
As per the scope of the report, ophthalmology is a branch of medical sciences, that deals with the structure, function, and various diseases related to the eye. The ophthalmic devices are medical equipment designed for diagnosis, surgical, and vision correction purposes. The France Ophthalmic Devices Market is segmented by Devices (Surgical Devices, Diagnostic and Monitoring Devices, Vision Correction Devices). The report offers the value (in USD million) for the above segments.
By Device Type | Diagnostic & Monitoring Devices | OCT Scanners | ||
Fundus & Retinal Cameras | ||||
Autorefractors & Keratometers | ||||
Corneal Topography Systems | ||||
Ultrasound Imaging Systems | Excimer Lasers | |||
Perimeters & Tonometers | Femtosecond Lasers | |||
Other Diagnostic & Monitoring Devices | YAG Lasers | |||
Surgical Devices | Cataract Surgical Devices | |||
Vitreoretinal Surgical Devices | ||||
Refreactive Surgical Devices | ||||
Glaucoma Surgical Devices | ||||
Other Surgical Devices | ||||
Vision Care Devices | Spectacles Frames & Lenses | |||
Contact Lenses | ||||
By Disease Indication | Cataract | |||
Glaucoma | ||||
Diabetic Retinopathy | Soft Contact Lenses | |||
Other Disease Indications | Rigid Gas-Permeable Lenses | |||
By End-user | Hospitals | |||
Specialty Ophthalmic Clinics | ||||
Ambulatory Surgery Centers (ASCs) | ||||
Other End-users |
Diagnostic & Monitoring Devices | OCT Scanners | ||
Fundus & Retinal Cameras | |||
Autorefractors & Keratometers | |||
Corneal Topography Systems | |||
Ultrasound Imaging Systems | Excimer Lasers | ||
Perimeters & Tonometers | Femtosecond Lasers | ||
Other Diagnostic & Monitoring Devices | YAG Lasers | ||
Surgical Devices | Cataract Surgical Devices | ||
Vitreoretinal Surgical Devices | |||
Refreactive Surgical Devices | |||
Glaucoma Surgical Devices | |||
Other Surgical Devices | |||
Vision Care Devices | Spectacles Frames & Lenses | ||
Contact Lenses |
Cataract | |
Glaucoma | |
Diabetic Retinopathy | Soft Contact Lenses |
Other Disease Indications | Rigid Gas-Permeable Lenses |
Hospitals |
Specialty Ophthalmic Clinics |
Ambulatory Surgery Centers (ASCs) |
Other End-users |
Key Questions Answered in the Report
What is the current value of the France ophthalmic devices market?
The France ophthalmic devices market size is USD 2.53 billion in 2025.
How fast is the market expected to grow?
Analysts forecast a 7.80% CAGR from 2025 to 2030, driving value to USD 3.68 billion by the end of the period.
Which device category holds the largest share?
Vision Care dominates with 63.0% of the France ophthalmic devices market share, led by EssilorLuxottica’s extensive eyewear and contact-lens portfolio.
Why are ambulatory surgery centers growing so quickly?
Government policy aims to push eligible procedures to outpatient settings, and ASCs offer lower costs and faster turnaround, resulting in an 8.98% CAGR.
What is the biggest growth opportunity by disease indication?
Diabetic-retinopathy devices are expanding at a 9.11% CAGR due to national screening programs and AI-driven diagnostic platforms.
How do reimbursement rules affect device adoption?
Stringent HAS evaluations can delay market entry for novel devices, reducing near-term uptake but incentivizing strong clinical-evidence generation for long-term success.
Page last updated on: June 11, 2025